Objectives: To evaluate the maintenance and improvement in clinical efficacy between week 12 and 24 in patients with rheumatoid arthritis (RA) treated with SB4 or ETN from a post-hoc analysis of phase III results. Methods: Patients with RA were randomised to receive 50 mg/week of either SB4 or ETN with background methotrexate. American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) responses were compared at week 12 and week 24. At week 12, patients with available assessment results were categorised as ACR responders or ACR non-responders and EULAR responders (patients with moderate or good EULAR response) or EULAR nonresponders. The same was assessed for week 24 and patients with missing data at week 24 were regarded as non-responders. Results: A total of 551 patients (283 patients from SB4 and 268 patients from ETN) completed 24 weeks of the study. In both treatment groups, efficacy was well maintained between week 12 and week 24. Among patients who were ACR20, 50, or 70 responders at week 12, 90.8% vs. 91.4%, 80.5% vs. 80.6%, and 74.5 vs. 77.5% of patients from SB4 and ETN, respectively, maintained their responses at week 24. Likewise, EULAR response was maintained by 93.1% vs. 92.6% of patients who had a good or moderate response at week 12. (Table) . The improvement in ACR responses between week 12 and 24 was comparable between SB4 and ETN group (Table) . In SB4 and ETN, respectively, 42.1% vs. 50.5% of 12-week ACR20 non-responders became ACR20 responders at week 24. Similarly, 20.9% vs. 21.9% of 12-week ACR50 non-responders became ACR50 responders and 13.0% vs. 11.4% of 12-week ACR70 non-responders became ACR70 responders. The improvement in EULAR responses was also comparable between SB4 and ETN. 43.2% vs. 52.2% of 12-week EULAR nonresponders in SB4 and ETN, respectively, became EULAR responders at week 24.
remission even using biological therapy. DNAse activity of the blood serum and antinuclear antibody may be useful in this context. Changes of serum DNase activity in the RA treatment by biological agents previously have been not investigated. Objectives: The aim of this work is to study the dynamics clinical and laboratory parameters, DNAse serum activity and ANA during the RA treatment by infliximab (INF) and assess the prognostic potential of them in prediction of response to INF. Methods: 24 RA patients were involved in the study. All patients fulfilled the EULAR/ACR 2010 RA criteria. 22/24 patients received 6 infusions of INF at a dose of 3 mg/kg according to standard protocol: at 0th, 2th, 6th and then every 8 week. 2/24 patient received 4 infusions of INF. All patients received synthetic DMARDs therapy by metotrexate (10-17,5 mg weekly), 18/24 patients received glucocorticoids (methylprednisolone 4-8 mg daily) and non-steroidal anti-inflammatory drugs. Prior to treatment by INF patients did not receive any biological agents. All patients had high disease activity before INF treatment (DAS28<5,1). ANA determination was performed by indirect immunofluorescence on Hep-2 cells using digital system AKLIDES. ANA was measured in serum samples before 1st INF administration, at 22-30 weeks after the 1st INF administration. To determine the DNAse activity of serum the method of rivanol clot was used. DNase activity was measured in serum samples before 1st INF administration, at 6 weeks after the 1st INF administration, at 30 week of treatment. Results: At week 30, ACR70 improvement reached 5/22 of the patients, ACR50 -10/22 of the patients, ACR20 -4/24 of patients. At 30 weeks of treatment by INF 2/22 of patients achieved remission (SDAI<3,3), 10/22 -a low disease activity (3,3 <SDAI ≤11). 13/24 patients were ANA-positive before INF treatment, 12/22 -after 24 weeks of treatment. Levels of serum DNase activity did not differ before and during the INF treatment (p>0,05). For assessment prognostic value of laboratory signs for INF response prediction logistic regression was used. Prognostic model, which included changes in ANA ( ANA) and DNAse serum activity level ( DNAse serum activity), anti-CCP-and RF-negativity was better (p=0,02) (area under ROC-curve =1,0; 95% CI 0,844-1,00 p=0,0001) than the model, which included only anti-CCP-and RF-negativity (area under ROC-curve =0,795; 95% CI 0,597-0,924, p=0,0141).
Conclusions:
The study confirmed the efficacy of RA treatment by INF for anti-CCP and RF negative patients. DNAse serum activity and ANA may be used as additional prognostic biomarker of INF response. For the assessment DNAse activity as marker of response to therapy is needed futher investigations with more number of patients. Background: Biological drugs exhibit excellent efficacy and continuity in the treatment of rheumatoid arthritis (RA) and play an important role in RA treatment. Blood concentration is an important factor in the efficacy of biological drugs, particularly antibody drugs. Infliximab (IFX) is an antibody drug against TNF-α and is reported to require a blood concentration of ≥1 μg/mL to be effective. Objectives: To investigate whether clinical efficacy can be predicted based on blood concentrations at the fourth dose of IFX in patients with RA. Methods: This study included 56 patients with RA who were treated with IFX. Patients included 13 men and 43 women aged from 26 to 81 years (mean, 60.3 years). The IFX concentration was measured immediately before administering the fourth IFX dose (8 weeks after administering the third dose). We then investigated the relationship between subsequent IFX efficacy and IFX concentration immediately before the fourth dose of IFX in these patients with RA. Concentrations were measured in stored frozen serum by using the ELISA method. Results: The IFX concentration immediately before the fourth dose was ≥1 μg/mL in 32 patients (≥1 μg/mL group) and <1 μg/mL in 24 patients (<1 μg/mL group). At the fourth dose, IFX was effective in 30 patients (93.8%) in the ≥1 μg/mL group, at a mean concentration of 5.18 μg/mL, while the mean concentration was 5.69 μg/mL for the remaining 2 non-responders. IFX was also effective in 21 patients (87.5%) in the <1 μg/mL group but did not elicit any response in the other 3 patients. At this point, all 5 non-responsive patients were primary non-responders. Of all 51 responders, 58.8% were in the ≥1 μg/mL group and 41.2% were in the <1 μg/mL group. Based on the data, we observed no relationship between efficacy and IFX concentration. After 1 year of IFX treatment, 36 of the 56 patients were responsive and 20 were non-responsive. In the 2 groups, 26 responsive patients (63.9%) and 9 non-responsive patients (45.0%) had an IFX concentration of ≥1 μg/mL immediately before the fourth dose. Conclusions: At the fourth dose, many of the patients with an IFX concentration of <1 μg/mL were also responsive to the treatment, so future efficacy was difficult to predict based on IFX concentration. In other words, during clinical Background: Biologic therapy has been a major change in Rheumatoid Arthritis (RA) prognosis, but around 40% of patients (pts) fail to respond. Part of this treatment failure can be explained by the development of anti-drug antibodies (ADA), but the ADA-associated secondary inefficacies rate is currently unclear Objectives: To assess in our AR cohort treated with Adalimumab (Ada), Infliximab (Ifx), etanercept (Etn), certolizumab (Czp), Tocilizumab (Tcz) and Abatacept (Abt) as 1st biologic agent, the frequency of drug suspension as well as the main causes for discontinuation and the secondary inefficacy rate associated with the development of immunogenicity Methods: From the RA cohort that initiated their 1st biologic agent at Hospital La Paz between 2005 and 2016, only those who had suspended those drugs were included, and causes for suspension were collected. Clinical activity was measured by DAS28 and Delta-DAS28 at 6 months of treatment to classify discontinuation by primary or secondary inefficacy. Drug levels (DL) and/or ADA were also measured by ELISA at 6 months since initiating the biologic agent in 43 pts and at drug discontinuation in 59 pts. Primary inefficacy was defined as DAS28>3.2 and delta-DAS28 <1.2 at 6 months with DL present. Secondary inefficacy was defined both as DAS28>3.2 plus delta-DAS28 <1.2 at 6 months with ADA+ and Delta-DAS28>1.2 or DAS28 <3.2 at 6 months with subsequent loss of efficacy. Statistical analysis was performed using SPSS version 20.0 Results: From the 246 pts who started their first biologic therapy, 144 (58%) pts who had definitively discontinued were included. [Ifx (n 35, 24%), Ada (n 40, 28%), Etn (n 30, 21%), Czp (n 23, 16%), Tcz (n 10, 7%) y Abt (n 6, 4%)]. 116 (80,6%) were women. The mean age was 56.3±14.7 years. The mean time of biologic was 2.23±1.96 years. From the global cohort, 18 (12.5%) drop out the treatment due to primary inefficacy, 41 (28.5%) to secondary inefficacy, 57 (39.6%) to adverse effects (AE), 11 (7.6%) to remission and 17 (11.8%) to other causes (surgery, pregnancy, etc.). 12.5% pts who discontinued due to AE or other causes had also a primary or secondary inefficacy; by including those pts in these last causes for suspension, a total of 20 pts (14%) failed due to primary inefficacy and 57 pts (39.6%) to secondary inefficacy. The most frequent AEs were: infections (35%), cutaneous AEs (psoriasis, rash, etc. (10.5%), infusion reactions (9%) and neoplasia (9%). Of the 59 pts who had DL/ADA measured at drug discontinuation, 42.4% were ADA +. Within the group that failed due to secondary inefficacy and had DL/ADA determined, 50% were ADA+; nevertheless this rate was smaller in suspensions due to other causes. Likewise, in the ADA+ pts, 73% suspended due to secondary inefficacy Conclusions: In our RA cohort, adverse effects were the main cause for discontinuation, with infections at 1st place. The 2nd cause conditioning interruption was the secondary inefficacy, in which 50% of our pts were ADA+ at drug
